A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease

[1]  F. Ginhoux,et al.  Targeting innate immunity for neurodegenerative disorders of the central nervous system , 2016, Journal of neurochemistry.

[2]  K. Ravichandran,et al.  Do not let death do us part: ‘find-me’ signals in communication between dying cells and the phagocytes , 2016, Cell Death and Differentiation.

[3]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[4]  J. Ávila,et al.  Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo. , 2015, Journal of Alzheimer's disease : JAD.

[5]  D. Castillo-Carranza,et al.  Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease , 2015, Front. Cell. Neurosci..

[6]  M. Pardon.  Lipopolysaccharide hyporesponsiveness: protective or damaging response to the brain? , 2015, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[7]  L. Tan,et al.  Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. , 2015, Journal of Alzheimer's disease : JAD.

[8]  Andrew H. Miller,et al.  The role of inflammation in depression: from evolutionary imperative to modern treatment target , 2015, Nature Reviews Immunology.

[9]  D. Lambert,et al.  Exploring LPS-induced sepsis in rats and mice as a model to study potential protective effects of the nociceptin/orphanin FQ system , 2014, Peptides.

[10]  N. Zilka,et al.  Microglia display modest phagocytic capacity for extracellular tau oligomers , 2014, Journal of Neuroinflammation.

[11]  Bradley T. Hyman,et al.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease , 2014, Acta Neuropathologica.

[12]  N. Rothwell,et al.  The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial , 2014, Journal of Neuroinflammation.

[13]  B. Jenkins,et al.  R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease , 2013, Brain Research.

[14]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[15]  T. A. D. A. P. T. Group.  Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) , 2013, Alzheimer's & Dementia.

[16]  D. Eliezer,et al.  Structural transitions in tau k18 on micelle binding suggest a hierarchy in the efficacy of individual microtubule‐binding repeats in filament nucleation , 2013, Protein science : a publication of the Protein Society.

[17]  P. Davies,et al.  Tau release from hTau mouse primary neuronal cultures , 2013, Alzheimer's & Dementia.

[18]  J. Rawlins,et al.  Systemic inflammation induces acute working memory deficits in the primed brain: relevance for delirium , 2012, Neurobiology of Aging.

[19]  N. Tabet,et al.  Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. , 2012, The Cochrane database of systematic reviews.

[20]  Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways , 2012, Journal of Neuroinflammation.

[21]  J. Growdon,et al.  Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. , 2011, The American journal of pathology.

[22]  P. Sawchenko,et al.  Lipopolysaccharide‐induced tau phosphorylation and kinase activity – modulation, but not mediation, by corticotropin‐releasing factor receptors , 2011, The European journal of neuroscience.

[23]  Thomas E Lane,et al.  Inflammation induced by infection potentiates tau pathological features in transgenic mice. , 2011, The American journal of pathology.

[24]  R. Ransohoff,et al.  Regulation of Tau Pathology by the Microglial Fractalkine Receptor , 2010, Neuron.

[25]  D. Morgan,et al.  LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice , 2010, Journal of Neuroinflammation.

[26]  S. M. Robinson,et al.  Minimal penetration of lipopolysaccharide across the murine blood–brain barrier , 2010, Brain, Behavior, and Immunity.

[27]  M. Wozniak,et al.  Alzheimer's disease and infection: Do infectious agents contribute to progression of Alzheimer's disease? , 2009, Alzheimer's & Dementia.

[28]  W. Bowers,et al.  Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. , 2009, The American journal of pathology.

[29]  V. Thulasiraman,et al.  Use of an antibody-coupled array and mass spectrometry for simultaneous detection of multiple amyloid beta fragments , 2009, Alzheimer's & Dementia.

[30]  K. Honjo,et al.  Alzheimer's disease and infection: Do infectious agents contribute to progression of Alzheimer's disease? , 2009, Alzheimer's & Dementia.

[31]  W. Noble,et al.  Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  F. LaFerla,et al.  Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. , 2008, The American journal of pathology.

[33]  Z. Khachaturian.  Alzheimer's & Dementia: The Journal of the Alzheimer's Association , 2008, Alzheimer's & Dementia.

[34]  Donald R. Miller,et al.  Protective effects of NSAIDs on the development of Alzheimer disease , 2008, Neurology.

[35]  B. Jenkins,et al.  Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice , 2008, Brain Research.

[36]  D. Cribbs,et al.  Phagocytosis of Amyloid-β and Inflammation: Two Faces of Innate Immunity in Alzheimer's Disease , 2007 .

[37]  D. Cribbs,et al.  Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.

[38]  Q. Smith,et al.  Brain Uptake of Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen, Flurbiprofen, and Indomethacin , 2006, Pharmaceutical Research.

[39]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[40]  Alexandra Flemming,et al.  Infectious disease: Unravelling SARS lethality , 2005, Nature Reviews Drug Discovery.

[41]  Jesus Avila,et al.  Role of tau protein in both physiological and pathological conditions. , 2004, Physiological reviews.

[42]  P. Davies,et al.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms , 2003, Journal of neurochemistry.

[43]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[44]  S. Barger,et al.  Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway , 2003, The Journal of Neuroscience.

[45]  Y. L. Dubreuil,et al.  Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Academia de Știinţe Medicale.  Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie , 1990 .